Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 8, 2007 Brian Lawler	Millennium Looks Ahead Shares of the biopharmaceutical company ended the year more than 10% higher, despite the presence of increased competition for its cancer treatment Velcade and all sorts of attempted merger and acquisition activity within the company. The pharmaceutical foresees a mixed 2007.
The Motley Fool December 27, 2007 Brian Lawler	A New Era at Millennium? Millennium Pharmaceuticals submits a supplemental New Drug Application with the FDA to expand the use of lead drug Velcade to patients with multiple myeloma.
The Motley Fool July 22, 2004 Charly Travers	A Millennium Pharmaceuticals Mix Sales for one drug are encouraging, while sales for another one are declining.
The Motley Fool April 30, 2007 Brian Lawler	The Future Millennium Isn't So Exciting Biotech drugmaker Millennium Pharmaceuticals released its quarterly financial results. Investors, take note.
The Motley Fool November 6, 2007 Brian Lawler	It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results.
The Motley Fool January 31, 2008 Brian Lawler	Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug.
The Motley Fool July 27, 2007 Brian Lawler	Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance.
The Motley Fool October 9, 2006 Brian Lawler	Much-Needed Publicity for Millennium Millennium Pharmaceuticals' cancer-fighting drug Velcade is set to gain exposure for a new treatment. Investors, take note.
The Motley Fool December 15, 2003 W.D. Crotty	Millennium Celebration Millennium took just four and a half years to push Velcade from first human dose to FDA approval, and the company has financial muscle most biotechnology companies only dream about.
The Motley Fool October 30, 2006 Brian Lawler	Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note.
BusinessWeek July 21, 2003 Gene G. Marcial	A Rosier Millennium? Jump into Millennium Pharmaceuticals stock. That's the word from some Millennium trackers who think its recent fall -- from 17.20 in mid-June to 14 on July 1 -- was unwarranted. It is now at 15.
Pharmaceutical Executive July 1, 2006 Deborah Dunsire	Thoughtleader: Targeted Expansion Millennium Pharmaceuticals' CEO discusses what's ahead for the company, its success through partnerships, and why it believes it can lead the pack in targeted therapeutics.
The Motley Fool September 27, 2006 Brian Lawler	Enormous Interest in AnorMED Genzyme and Millenium vie to purchase the Canadian biotech. Shares of AnorMED currently trade for more than $12 a share.
The Motley Fool October 12, 2006 Brian Lawler	Genzyme Runs a Tight Ship Revenues are up at the biopharmaceutical company, but shares dropped in morning trading.
The Motley Fool January 13, 2009 Brian Orelli	Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool November 20, 2007 Brian Orelli	Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future.
The Motley Fool May 8, 2007 Brian Lawler	Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow.
The Motley Fool July 26, 2010 Brian Orelli	Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug.
The Motley Fool February 6, 2007 Brian Lawler	Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook.
Bio-IT World August 13, 2003 Branca et al.	Discovery Surges and Tools Deliver Market Compass for Q2 finds consolidation among drug discovery companies continuing, but market caps rising.
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
Bio-IT World January 13, 2003 Malorye Branca	Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry.
The Motley Fool February 18, 2004 Jeff Hwang	Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule.
The Motley Fool November 4, 2005 Stephen D. Simpson	A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals...
The Motley Fool December 7, 2009 Brian Orelli	When the Big Guns Come In, You Get Blasted Larger drug companies may want to gobble up smaller drug firms like Allos Therapeutics and Gloucester Pharmaceuticals.
The Motley Fool April 28, 2011 Brian Orelli	Celgene Gets No Love The market shrugs off a solid quarter.
The Motley Fool July 20, 2010 Brian Orelli	Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant.
The Motley Fool April 2, 2008 Brian Lawler	Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders.
The Motley Fool March 26, 2004 Charly Travers	Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs.
Pharmaceutical Executive February 1, 2014 William Looney	Takeda' Oncology Taskmaster Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge; and a lead position in the hotly contested search to make cancer a treatable disease.
Bio-IT World August 18, 2004	Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated.
The Motley Fool January 11, 2010 Brian Orelli	Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.
PC Magazine September 21, 2004	Doom 3 The original death match shooter has been revitalized for the new millennium, but it keeps things personal with a four-player-only mode that is true to the original game.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool March 1, 2005 Rich Smith	Dow Recharges Millennium Cell A new partnership with Dow Chemical may not do much for Millennium Cell investors, but it beats letting their company run out of juice.
The Motley Fool December 7, 2007 Brian Lawler	Drugmakers Gear Up for ASH Cancer-focused drugmakers will be presenting their most promising data at two premiere medical conferences. Investors, take note.
The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
The Motley Fool December 8, 2009 Brian Orelli	Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer.
The Motley Fool October 23, 2009 Brian Orelli	Not 50% Growth, but We'll Take It Double-digit growth is still pretty good for Celgene.